Literature DB >> 11704078

DHEA-S levels and depressive symptoms in a cohort of African American and Caucasian women in the late reproductive years.

M F Morrison1, T Ten Have, E W Freeman, M D Sammel, J A Grisso.   

Abstract

BACKGROUND: The objective of this study was to elucidate the associations of dehydroepiandrosterone sulfate (DHEA-S) levels and depressive symptoms in African American and Caucasian women in the late reproductive years, a transitional age zone preceding the perimenopause, in which ovarian aging and associated endocrine changes begin. We had hypothesized that lower levels of DHEA-S would be associated with depressive symptoms and that, because DHEA-S levels decline with increasing age, older women would have an increased prevalence of depressive symptoms.
METHODS: This cross-sectional study used a population-based urban sample recruited through random digit telephone dialing. The sample was 338 women between the ages of 35 and 47 years with regular menses. Half the sample was African American and half was Caucasian.
RESULTS: Higher DHEA-S levels were associated with depressive symptoms in women in the younger half of this cohort. Lower DHEA-S levels were associated with depressive symptoms in the women in the older half of this cohort. The direction of the relationship of DHEA-S and depressive symptoms changes with age, being a positive relationship in younger women and an inverse relationship in the older women in this cohort. This change in the direction of the relationship appears to occur at a younger age in African American women.
CONCLUSIONS: Our hypothesis of a relationship between low DHEA-S levels and elevated depressive symptoms was supported only in the older women in this cohort. Unexpectedly, younger women in this cohort demonstrated a positive association between DHEA-S levels and depressive symptoms. Changes in DHEA-S levels, depressive symptoms, and the relationship of other hormones in the hypothalamic-pituitary-adrenal axis need to be better understood in premenopausal women approaching perimenopause.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11704078     DOI: 10.1016/s0006-3223(01)01169-6

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  12 in total

Review 1.  Depression During and After the Perimenopause: Impact of Hormones, Genetics, and Environmental Determinants of Disease.

Authors:  Joyce T Bromberger; Cynthia Neill Epperson
Journal:  Obstet Gynecol Clin North Am       Date:  2018-10-25       Impact factor: 2.844

Review 2.  Neurosteroid, GABAergic and hypothalamic pituitary adrenal (HPA) axis regulation: what is the current state of knowledge in humans?

Authors:  Shannon K Crowley; Susan S Girdler
Journal:  Psychopharmacology (Berl)       Date:  2014-04-23       Impact factor: 4.530

3.  Higher DHEA-S (dehydroepiandrosterone sulfate) levels are associated with depressive symptoms during the menopausal transition: results from the PENN Ovarian Aging Study.

Authors:  Mary Frances Morrison; Ellen W Freeman; Hui Lin; Mary D Sammel
Journal:  Arch Womens Ment Health       Date:  2011-07-20       Impact factor: 3.633

Review 4.  Androgen therapy with dehydroepiandrosterone.

Authors:  Jacques Buvat
Journal:  World J Urol       Date:  2003-10-10       Impact factor: 4.226

5.  Late-life depressive symptoms are associated with both hyperactivity and hypoactivity of the hypothalamo-pituitary-adrenal axis.

Authors:  Brenda W J H Penninx; Aartjan T F Beekman; Stephania Bandinelli; Anna Maria Corsi; Marijke Bremmer; Witte J Hoogendijk; Jack M Guralnik; Luigi Ferrucci
Journal:  Am J Geriatr Psychiatry       Date:  2007-06       Impact factor: 4.105

6.  Pathways from racial discrimination to cortisol/DHEA imbalance: protective role of religious involvement.

Authors:  Daniel B Lee; Melissa K Peckins; Alison L Miller; Meredith O Hope; Enrique W Neblett; Shervin Assari; Jaime Muñoz-Velázquez; Marc A Zimmerman
Journal:  Ethn Health       Date:  2018-09-10       Impact factor: 2.772

7.  Symptomatic menopausal transition increases the risk of new-onset depressive disorder in later life: a nationwide prospective cohort study in Taiwan.

Authors:  Mu-Hong Chen; Tung-Ping Su; Cheng-Ta Li; Wen-Han Chang; Tzeng-Ji Chen; Ya-Mei Bai
Journal:  PLoS One       Date:  2013-03-27       Impact factor: 3.240

8.  Glucocorticoid Resistance: Is It a Requisite for Increased Cytokine Production in Depression? A Systematic Review and Meta-Analysis.

Authors:  Andrew J Perrin; Mark A Horowitz; Jacob Roelofs; Patricia A Zunszain; Carmine M Pariante
Journal:  Front Psychiatry       Date:  2019-06-28       Impact factor: 4.157

9.  Neuroactive steroids after estrogen exposure in depressed postmenopausal women treated with sertraline and asymptomatic postmenopausal women.

Authors:  Melinda L Morgan; Andrea J Rapkin; Giovanni Biggio; Mariangela Serra; Maria Giuseppina Pisu; Natalie Rasgon
Journal:  Arch Womens Ment Health       Date:  2009-09-03       Impact factor: 3.633

10.  Higher serum dehydroepiandrosterone sulfate protects against the onset of depression in the elderly: Findings from the English Longitudinal Study of Aging (ELSA).

Authors:  Luis H Souza-Teodoro; Cesar de Oliveira; Kate Walters; Livia A Carvalho
Journal:  Psychoneuroendocrinology       Date:  2015-11-12       Impact factor: 4.905

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.